Shandong Xinhua Pharmaceutical Group Company Limited (the "Company") is one of the Top 500 king-sized enterprises and a backbone pharmaceutical enterprise in China, to which 12 subsidiaries are affiliated with several kinds of ownership systems and an enterprise technical center in state-level is attached. The Company has more than 10,000 employees and about 3 billion RMB Yuan of assets. The property rights of the Company are managed by the means of share control, share participation, merge, transfer, auction, Joint Venture, cooperation etc. The products of the Company are manufactured and managed mainly in chemically-synthetic bulk pharmaceuticals, medical preparations and chemical raw materials, simultaneously in pharmaceutical intermediates, chemical corrosion-resistant equipment, pharmaceutical equipment, medical packaging materials etc. Moreover, the Company has renovated a plant manufacturing Traditional Chinese Medicines in order to develop the Traditional Chinese Medicines with a variety of dosage forms, such as Injections, Tablets, Capsules and Oral Liquids.

With implementing internationalized development strategy and adopting international advanced standards in quality management, the Company has passed the certifications in GMP, ISO9001, ISO14001, and ISO 10012. The main products of the Company have obtained COS Certificate from Europe and passed FDA auditing from USA.

"XINHUA" brand was honored with the title of "Chinese Famous Brand" in China. The Company ranked on the first list of enterprises which have been awarded such great honor since the new "Trade Mark Law" came into force in China.